Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • PR Newswire Amplify™
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • IR
  • All Products
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • IR
  • All Products
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Sign Up
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media Enquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR

Public advisory - Unauthorized and counterfeit health products seized at Thumbs Up 4 Shiatsu in Mississauga may pose serious health risks Français


News provided by

Health Canada (HC)

Mar 25, 2026, 16:54 ET

Share this article

Share toX

Share this article

Share toX

OTTAWA, ON, March 25, 2026 /CNW/ -

Summary

Tofacitinib Tablets IP 5 mg (CNW Group/Health Canada (HC))
Tofacitinib Tablets IP 5 mg (CNW Group/Health Canada (HC))
Rhofanib 5 (Tofacitinib 5 mg) (CNW Group/Health Canada (HC))
Rhofanib 5 (Tofacitinib 5 mg) (CNW Group/Health Canada (HC))
Haircare, Laboratoire Revitacare France (Hyaluronic acid 2 mg) (CNW Group/Health Canada (HC))
Haircare, Laboratoire Revitacare France (Hyaluronic acid 2 mg) (CNW Group/Health Canada (HC))
Bepanthen (Dekspantenol 500 mg/2 ml) (CNW Group/Health Canada (HC))
Bepanthen (Dekspantenol 500 mg/2 ml) (CNW Group/Health Canada (HC))
Bepacto (Dexpanthenol 500 mg/2 ml)) (CNW Group/Health Canada (HC))
Bepacto (Dexpanthenol 500 mg/2 ml)) (CNW Group/Health Canada (HC))
Biacto (Biotin 5 mg/1 ml) (CNW Group/Health Canada (HC))
Biacto (Biotin 5 mg/1 ml) (CNW Group/Health Canada (HC))
Mounjaro vials (tirzepatide) (CNW Group/Health Canada (HC))
Mounjaro vials (tirzepatide) (CNW Group/Health Canada (HC))
Mounjaro KwikPen (tirzepatide injection) (CNW Group/Health Canada (HC))
Mounjaro KwikPen (tirzepatide injection) (CNW Group/Health Canada (HC))
KwikPen (tirzepatide injection), Drug Identification Number (DIN) 03552000 and batch D856216 are invalid (CNW Group/Health Canada (HC))
KwikPen (tirzepatide injection), Drug Identification Number (DIN) 03552000 and batch D856216 are invalid (CNW Group/Health Canada (HC))
KwikPen (tirzepatide injection), Drug Identification Number (DIN) 03552000 and batch D856216 are invalid (CNW Group/Health Canada (HC))
KwikPen (tirzepatide injection), Drug Identification Number (DIN) 03552000 and batch D856216 are invalid (CNW Group/Health Canada (HC))
Tofacitinib Tablets IP 5 mg (CNW Group/Health Canada (HC)) Rhofanib 5 (Tofacitinib 5 mg) (CNW Group/Health Canada (HC)) Haircare, Laboratoire Revitacare France (Hyaluronic acid 2 mg) (CNW Group/Health Canada (HC)) Bepanthen (Dekspantenol 500 mg/2 ml) (CNW Group/Health Canada (HC)) Bepacto (Dexpanthenol 500 mg/2 ml)) (CNW Group/Health Canada (HC)) Biacto (Biotin 5 mg/1 ml) (CNW Group/Health Canada (HC)) Mounjaro vials (tirzepatide) (CNW Group/Health Canada (HC)) Mounjaro KwikPen (tirzepatide injection) (CNW Group/Health Canada (HC)) KwikPen (tirzepatide injection), Drug Identification Number (DIN) 03552000 and batch D856216 are invalid (CNW Group/Health Canada (HC)) KwikPen (tirzepatide injection), Drug Identification Number (DIN) 03552000 and batch D856216 are invalid (CNW Group/Health Canada (HC))
  • Product: Unauthorized and counterfeit health products, including prescription and injectable drugs.
  • Issue: Health products – Unauthorized and counterfeit products; Product safety
  • What to do: Do not use these products. Consult a licensed healthcare professional if you have been administered or have used these products and have health concerns.

Affected products

Unauthorized and counterfeit health products seized from Thumbs Up 4 Shiatsu (located at 3465 Semenyk Court, 2nd floor, Mississauga, Ontario), including:

Category

Product name

Unauthorized health products containing prescription drugs

Tofacitinib Tablets IP 5 mg

Rhofanib 5 (Tofacitinib 5 mg)

Haircare, Laboratoire Revitacare France (Hyaluronic acid 2 mg)

Unauthorized injectable drugs

Bepanthen (Dekspantenol 500 mg/2 ml)

Bepacto (Dexpanthenol 500 mg/2 ml))

Biacto (Biotin 5 mg/1 ml)

Counterfeit health  products

Mounjaro vials (tirzepatide)

Mounjaro KwikPen (tirzepatide injection) 

KwikPen (tirzepatide injection), Drug Identification Number (DIN) 03552000 and batch D856216 are invalid

Issue

Health Canada is warning consumers about multiple unauthorized and counterfeit health products seized at Thumbs Up 4 Shiatsu in Mississauga, Ontario. Health Canada has not authorized any of the health products that were seized, which means that they have not been assessed for safety, efficacy and quality. Selling unauthorized or counterfeit health products is illegal.

The seized products, including injectables are labelled to contain prescription or other drug ingredients. These products may have been sold or administered for pain management, hair loss, weight management or other cosmetic purposes.

Counterfeit drugs are made to look like authentic products, but they are not the same and they may not contain the drug at all. Though some of the counterfeit products are labelled with DINs, which may lead consumers to believe the products were authorized, the manufacturer of Mounjaro has confirmed that the seized products are counterfeit. The best way to make sure your prescription drugs are authentic is to buy them from a licensed pharmacy with a prescription from a healthcare professional. Prescription drugs cannot be sold outside of a licensed pharmacy and should only be taken under the care of a healthcare professional because they are used to treat specific health conditions and may pose serious health risks.

Unauthorized or counterfeit health products may:

  • Interact with other medications an individual might be taking.
  • Contain too much, too little, or none of the active ingredient.
  • Contain high-risk ingredients, additives, or contaminants that may or may not be listed on the label.
  • Have not been manufactured or stored safely.

Unauthorized or counterfeit injectable drugs carry additional risks, including infections, scarring, allergic reactions, and other serious adverse outcomes due to contamination, improper handling, or unsafe administration.

Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety.

What you should do

  • Do not buy or use unauthorized or counterfeit health products. When receiving cosmetic treatments, read product labels (or ask your healthcare professional to show you the product label) to confirm a product has been authorized for sale by Health Canada. Authorized health products have an eight-digit DIN, Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM).
    • You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database, Licensed Natural Health Product Database or the Medical Devices Active Licences Listing (MDALL).
  • Only buy prescription drugs from licensed pharmacies.
  • Consult a licensed healthcare professional (physician, nurse practitioner, pharmacist) if you have been administered or have used unauthorized health products and have health concerns.
  • Report any health product-related side effects or complaints to Health Canada.
  • Learn more about buying health products safely: 
    • Buying drugs over the Internet
    • Adulteration of natural health products
    • Risks of buying natural health products online
    • The safe use of health products for weight loss
    • Safe Use of Bodybuilding Products - Canada.ca
    • Buying medical devices from internet

Background

Tirzepatide is available only by prescription in Canada for the treatment of adults with type 2 diabetes (under the brand name Mounjaro) or for chronic-weight management (under the brand name Zepbound). Tirzepatide can be associated with significant risks, which include gastrointestinal side effects (nausea, vomiting and diarrhea), pancreatitis, worsening kidney function, worsening depression or suicidal thoughts, hypoglycemia (low blood sugar when combined with other diabetes drugs), potential thyroid tumours, diabetic retinopathy (eye) complications, hypersensitivity reactions (i.e., allergic responses, including anaphylactic reactions), and delayed gastric emptying (i.e., the stomach taking too long to empty food into the small intestine) that may pose risks if the patient is undergoing a procedure which requires sedation. Tirzepatide should not be taken by pregnant or breastfeeding women.

Tofacitinib, also known under the brand name Rhofanib, is a prescription medication that affects the immune system and that is only approved to treat specific medical conditions (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis ulcerative colitis and juvenile idiopathic arthritis) at recommended doses. Taking tofacitinib for other uses without guidance from a licensed healthcare professional can pose serious health risks. The medication suppresses parts of the immune system and may increase the risk of infections, blood clots, cardiovascular events, and certain cancers, particularly if taken without proper medical oversight. The risks may be greater for certain patient populations, including older adults, individuals with a history of cardiovascular disease, smokers, or those with weakened immune systems or chronic infections. Patients should be supervised by a qualified healthcare professional with appropriate screening and follow-up to track side effects and to prevent complications. 

SOURCE Health Canada (HC)

Media Enquiries: Health Canada, (613) 957-2983, [email protected]; Public Enquiries: (613) 957-2991, 866 225-0709, [email protected]

Modal title

Organization Profile

Health Canada (HC)

    Also from this source

  • Joint Statement from the Acting Chief Public Health Officer of Canada and the Chief Medical Officer of Public Health for Indigenous Services Canada on World Tuberculosis Day

  • Government of Canada announces reappointment to the Canadian Institutes of Health Research Governing Council

  • New Task Force to enhance Canada's competitiveness and improve access to innovative medicines

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Platform Login
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.